FDA Delays Novo Diabetes Drugs Over Heart Risks
The U.S. Food and Drug Administration will require an additional clinical trial before approving Novo Nordisk A/S' proposed diabetes treatments Tresiba and Ryzodeg, the company announced Sunday, amid concerns about an...To view the full article, register now.
Already a subscriber? Click here to view full article